首页> 外文期刊>Journal of Neurology, Neurosurgery and Psychiatry >Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives.
【24h】

Inherited thrombophilia and stratification of ischaemic stroke risk among users of oral contraceptives.

机译:口服避孕药使用者的遗传性血栓形成和缺血性卒中风险分层。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Whether use of oral contraceptives is a risk factor for arterial ischaemic stroke is controversial. In particular, few data are available on what criteria should be adopted to establish an individual profile of risk before the start of oral contraceptives. PATIENTS AND METHODS: The effects of oral contraceptives and their interaction with the G1691A polymorphisms of the factor V gene, the G20210A polymorphisms of the prothrombin gene and the C677T polymorphisms of the MTHFR gene on the risk of cerebral ischaemia were determined in a series of 108 consecutive women aged <45 years with ischaemic stroke and 216 controls, in a hospital-based case-control study design. RESULTS: Use of oral contraceptives was associated with an increased risk of cerebral ischaemia (odds ratio (OR) 3.95; 95% confidence interval (CI) 2.29 to 6.78). ORs for stroke were 2.25 (95% CI 1.15 to 4.40), 3.94 (95% CI 2.28 to 6.81) and 8.87 (95% CI 3.72 to 21.1) for non-oral contraceptive users with the TT MTHFR genotype, oral contraceptive users without the TT MTHFR genotype and oral contraceptive users with the TT MTHFR genotype, respectively, when compared with non-oral contraceptive users without the TT MTHFR genotype, with a multiplicative independent effect. Compared with non-oral contraceptive users, ORs for stroke were 2.65 (95% CI 1.46 to 4.81) for oral contraceptive users with none of the studied polymorphisms and 22.8 (95% CI 4.46 to 116.00) for oral contraceptive users with at least one of the studied polymorphisms, with a synergistic effect. CONCLUSIONS: Exposure to the effects of oral contraceptives may increase the risk of ischaemic stroke in women with an inherited prothrombotic background. Testing for these genetic variants may allow more accurate stratification of the population at risk before long-term use of oral contraceptives is prescribed.
机译:背景:使用口服避孕药是否是动脉缺血性中风的危险因素尚有争议。特别是,在开始使用口服避孕药之前,关于采用何种标准建立个人风险概况的数据很少。患者和方法:通过一系列的108项研究确定了口服避孕药及其与因子V基因的G1691A多态性,凝血酶原基因的G20210A多态性和MTHFR基因的C677T多态性的相互作用对脑缺血风险的影响一项基于医院的病例对照研究设计中,连续<45岁且患有缺血性卒中和216名对照的女性。结果:口服避孕药与脑缺血风险增加相关(几率(OR)3.95; 95%置信区间(CI)2.29至6.78)。对于具有TT MTHFR基因型的非口服避孕药使用者,未使用TT MTHFR基因型的非口服避孕药使用者,卒中的OR为2.25(95%CI 1.15至4.40),3.94(95%CI 2.28至6.81)和8.87(95%CI 3.72至21.1)。与没有TT MTHFR基因型的非口服避孕药使用者相比,TT MTHFR基因型和具有TT MTHFR基因型口服药使用者分别具有乘法独立效应。与非口服避孕药使用者相比,没有研究多态性的口服避孕药使用者的卒中OR值为2.65(95%CI 1.46至4.81),而口服避孕药使用者至少有以下一项的卒中OR为22.8(95%CI 4.46至116.00)。研究的多态性,具有协同作用。结论:暴露于口服避孕药的作用可能增加具有血栓形成背景的女性发生缺血性中风的风险。在开处方长期使用口服避孕药之前,对这些遗传变异进行测试可以使处于危险中的人群更准确地分层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号